Daryl C. Drummond

10.2k total citations · 2 hit papers
102 papers, 8.0k citations indexed

About

Daryl C. Drummond is a scholar working on Molecular Biology, Biomaterials and Oncology. According to data from OpenAlex, Daryl C. Drummond has authored 102 papers receiving a total of 8.0k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Molecular Biology, 42 papers in Biomaterials and 30 papers in Oncology. Recurrent topics in Daryl C. Drummond's work include Nanoparticle-Based Drug Delivery (42 papers), Monoclonal and Polyclonal Antibodies Research (24 papers) and Cancer therapeutics and mechanisms (19 papers). Daryl C. Drummond is often cited by papers focused on Nanoparticle-Based Drug Delivery (42 papers), Monoclonal and Polyclonal Antibodies Research (24 papers) and Cancer therapeutics and mechanisms (19 papers). Daryl C. Drummond collaborates with scholars based in United States, Canada and China. Daryl C. Drummond's co-authors include Dmitri B. Kirpotin, Keelung Hong, John W. Park, Charles O. Noble, Christopher C. Benz, James D. Marks, Demetrios Papahadjopoulos, Olivier Meyer, Zexiong Guo and Jean‐Christophe Leroux and has published in prestigious journals such as Journal of Clinical Oncology, Nano Letters and Journal of Molecular Biology.

In The Last Decade

Daryl C. Drummond

102 papers receiving 7.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors

1999 1.0k citations Daryl C. Drummond, Keelung Hong et al. profile →
Antibody Targeting of Long-Circulating Lipidic Nanoparticles Does Not Increase Tumor Localization but Does Increase Internalization in Animal Models

2006 863 citations Dmitri B. Kirpotin, Daryl C. Drummond et al. Cancer Research profile →

Peers

Countries citing papers authored by Daryl C. Drummond

Since Specialization

Citations

This map shows the geographic impact of Daryl C. Drummond's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daryl C. Drummond with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daryl C. Drummond more than expected).

Fields of papers citing papers by Daryl C. Drummond

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daryl C. Drummond. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daryl C. Drummond. The network helps show where Daryl C. Drummond may publish in the future.

Co-authorship network of co-authors of Daryl C. Drummond

This figure shows the co-authorship network connecting the top 25 collaborators of Daryl C. Drummond. A scholar is included among the top collaborators of Daryl C. Drummond based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daryl C. Drummond. Daryl C. Drummond is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Synergy between EphA2-ILs-DTXp, a Novel EphA2-Targeted Nanoliposomal Taxane, and PD-1 Inhibitors in Preclinical Tumor Models 2019 ·Molecular Cancer Therapeutics ·Walid S. Kamoun, Anne‐Sophie Dugast, James Suchy, Stephanie Grabow, Ross B. Fulton, (unknown), Lia Luus, (unknown), Alexander Koshkaryev, Gang Sun, Vasileios Askoxylakis, Eric M. Tam, Zhaohua Huang, Daryl C. Drummond, Andrew J. Sawyer	15
2	Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs 2019 ·Journal of Controlled Release ·Zhaohua Huang, Suresh K. Tipparaju, Dmitri B. Kirpotin, Christine Pien, Tad Kornaga, Charles O. Noble, Alexander Koshkaryev, (unknown), Walid S. Kamoun, Daryl C. Drummond	33
3	Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer 2018 ·Clinical Cancer Research ·(unknown), Emily A. Pace, Sharlene Adams, Michael D. Curley, Victoria Rimkunas, Lin Nie, (unknown), Troy Bloom, Sergio Iadevaia, Jason Baum, (unknown), Akos Czibere, Chrystal U. Louis, Daryl C. Drummond, Ulrik B. Nielsen, Birgit Schoeberl, J. Marc Pipas, Robert M. Straubinger, Vasileios Askoxylakis, Alexey A. Lugovskoy	44
4	Modeling chemotherapy-induced stress to identify rational combination therapies in the DNA damage response pathway 2018 ·Science Signaling ·Ozan Alkan, Birgit Schoeberl, (unknown), Alexander Koshkaryev, Tim Heinemann, Daryl C. Drummond, Michael B. Yaffe, Andreas Raue	19
5	Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study 2017 ·Clinical Cancer Research ·Ramesh K. Ramanathan, Ronald L. Korn, Natarajan Raghunand, Jasgit C. Sachdev, (unknown), Gayle Jameson, Gerald J. Fetterly, Joshua Prey, Stephan G. Klinz, Jaeyeon Kim, Jason E. Cain, Bart S. Hendriks, Daryl C. Drummond, Eliel Bayever, Jonathan B. Fitzgerald	134
6	Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer 2017 ·Anti-Cancer Drugs ·Shannon C. Leonard, Helen Lee, Daniel F. Gaddy, Stephan G. Klinz, Nancy Paz, Ashish Kalra, Daryl C. Drummond, Daniel C. Chan, Paul A. Bunn, Jonathan B. Fitzgerald, Bart S. Hendriks	25
7	Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression 2015 ·Clinical Cancer Research ·Min H. Kang, Jing Wang, Monish Ram Makena, (unknown), Nancy Paz, (unknown), Michael M. Song, Ruben I. Calderon, (unknown), Ashly Hindle, (unknown), Jonathan B. Fitzgerald, Daryl C. Drummond, Timothy J. Triche, C. Patrick Reynolds	85
8	Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug Conversion 2014 ·Cancer Research ·Ashish Kalra, Jaeyeon Kim, Stephan G. Klinz, Nancy Paz, Jason E. Cain, Daryl C. Drummond, Ulrik B. Nielsen, Jonathan B. Fitzgerald	151
9	HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity 2012 ·Toxicology and Applied Pharmacology ·Joseph G. Reynolds, Elena Geretti, Bart S. Hendriks, Helen Lee, Shannon C. Leonard, Stephan G. Klinz, Charles O. Noble, (unknown), Peter W. Zandstra, Daryl C. Drummond, Kenneth J. Olivier, Ulrik B. Nielsen, Clet Niyikiza, Samuel Agresta, Thomas J. Wickham	93
10	Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies 2008 ·Molecular Cancer Therapeutics ·Feng An, Daryl C. Drummond, Shannon M. Wilson, Dmitri B. Kirpotin, Stephen L. Nishimura, V. Courtney Broaddus, Bin Liu	37
11	Impact of Single-chain Fv Antibody Fragment Affinity on Nanoparticle Targeting of Epidermal Growth Factor Receptor-expressing Tumor Cells 2007 ·Journal of Molecular Biology ·Yu Zhou, Daryl C. Drummond, Hao Zou, Mark Hayes, Gregory P. Adams, Dmitri B. Kirpotin, James D. Marks	125
12	Antibody Targeting of Long-Circulating Lipidic Nanoparticles Does Not Increase Tumor Localization but Does Increase Internalization in Animal Models breakdown → 2006 ·Cancer Research ·Dmitri B. Kirpotin, Daryl C. Drummond, Yi Shao, M R Shalaby, Keelung Hong, Ulrik B. Nielsen, James D. Marks, Christopher C. Benz, John W. Park	863
13	Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts1 2006 ·Neuro-Oncology ·Yoji Yamashita, Michal T. Krauze, Tomohiro Kawaguchi, Charles O. Noble, Daryl C. Drummond, John W. Park, Krystof S. Bankiewicz	65
14	Extensive Distribution of Liposomes in Rodent Brains and Brain Tumors Following Convection-Enhanced Delivery 2004 ·Journal of Neuro-Oncology ·Christoph Mamot, John Nguyen, Michael Pourdehnad, Piotr Hadaczek, Ryuta Saito, John R. Bringas, Daryl C. Drummond, Keelung Hong, Dmitri B. Kirpotin, Tracy R. McKnight, Mitchel S. Berger, John W. Park, Krys S. Bankiewicz	110
15	Development of ligand-targeted liposomes for cancer therapy 2004 ·Expert Opinion on Therapeutic Targets ·Charles O. Noble, Dmitri B. Kirpotin, Mark Hayes, Christoph Mamot, Keelung Hong, John W. Park, Christopher C. Benz, James D. Marks, Daryl C. Drummond	119
16	Liposome-based approaches to overcome anticancer drug resistance 2003 ·Drug Resistance Updates ·Christoph Mamot, Daryl C. Drummond, Keelung Hong, Dmitri B. Kirpotin, John W. Park	135
17	In vitro characterization of a novel polymeric-based pH-sensitive liposome system 2000 ·Biochimica et Biophysica Acta (BBA) - Biomembranes ·Monia Zignani, Daryl C. Drummond, O. Meyer, Keelung Hong, Jean‐Christophe Leroux	78
18	Current status of pH-sensitive liposomes in drug delivery 2000 ·Progress in Lipid Research ·Daryl C. Drummond, Monia Zignani, Jean‐Christophe Leroux	381
19	Synthesis and characterization of N-acylated, pH-sensitive ‘caged’ aminophospholipids 1995 ·Chemistry and Physics of Lipids ·Daryl C. Drummond, (unknown)	32
20	The detection of rodent resistance to anticoagulants. 1973 ·PubMed ·Daryl C. Drummond, B. D. Rennison	27

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact